tetano
Editor, Senior Moderator
J Clin Microbiol
. 2020 Nov 2;JCM.02504-20.
doi: 10.1128/JCM.02504-20. Online ahead of print.
Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of antibody in human, canine, cat and hamster sera
Ranawaka A P M Perera[SUP] 1 [/SUP], Ronald Ko[SUP] 1 [/SUP], Owen T Y Tsang[SUP] 2 [/SUP], David S C Hui[SUP] 3 [/SUP], Mike Y M Kwan[SUP] 4 [/SUP], Christopher J Brackman[SUP] 5 [/SUP], Esther M W To[SUP] 5 [/SUP], Hui-Ling Yen[SUP] 1 [/SUP], Kathy Leung[SUP] 1 6 [/SUP], Samuel M S Cheng[SUP] 1 [/SUP], Kin Ho Chan[SUP] 1 [/SUP], Karl C K Chan[SUP] 1 [/SUP], Ka-Chi Li[SUP] 1 [/SUP], Linda Saif[SUP] 7 [/SUP], Vanessa R Barrs[SUP] 8 [/SUP], Joseph T Wu[SUP] 1 6 [/SUP], Thomas H C Sit[SUP] 5 [/SUP], Leo L M Poon[SUP] 1 9 [/SUP], Malik Peiris[SUP] 10 9 [/SUP]
Affiliations
Abstract
Surrogate neutralization assays for SARS-CoV-2 that can be done without biosafety-level-3 containment and in multiple species are desirable. We evaluate a recently developed surrogate virus neutralization test (sVNT) in comparison to 90% plaque reduction neutralization tests (PRNT[SUB]90[/SUB]) in human, canine, cat and hamster sera. With PRNT[SUB]90[/SUB] as reference, sVNT had sensitivity of 98.9% and specificity of 98.8% respectively. Using a panel of immune sera to other coronaviruses, we confirm the lack of cross reactivity to other coronaviruses in SARS-CoV-2 sVNT and PRNT[SUB]90[/SUB] assays, except for cross-reactivity to SARS-CoV-1 in sVNT.
. 2020 Nov 2;JCM.02504-20.
doi: 10.1128/JCM.02504-20. Online ahead of print.
Evaluation of a SARS-CoV-2 surrogate virus neutralization test for detection of antibody in human, canine, cat and hamster sera
Ranawaka A P M Perera[SUP] 1 [/SUP], Ronald Ko[SUP] 1 [/SUP], Owen T Y Tsang[SUP] 2 [/SUP], David S C Hui[SUP] 3 [/SUP], Mike Y M Kwan[SUP] 4 [/SUP], Christopher J Brackman[SUP] 5 [/SUP], Esther M W To[SUP] 5 [/SUP], Hui-Ling Yen[SUP] 1 [/SUP], Kathy Leung[SUP] 1 6 [/SUP], Samuel M S Cheng[SUP] 1 [/SUP], Kin Ho Chan[SUP] 1 [/SUP], Karl C K Chan[SUP] 1 [/SUP], Ka-Chi Li[SUP] 1 [/SUP], Linda Saif[SUP] 7 [/SUP], Vanessa R Barrs[SUP] 8 [/SUP], Joseph T Wu[SUP] 1 6 [/SUP], Thomas H C Sit[SUP] 5 [/SUP], Leo L M Poon[SUP] 1 9 [/SUP], Malik Peiris[SUP] 10 9 [/SUP]
Affiliations
- PMID: 33139421
- DOI: 10.1128/JCM.02504-20
Abstract
Surrogate neutralization assays for SARS-CoV-2 that can be done without biosafety-level-3 containment and in multiple species are desirable. We evaluate a recently developed surrogate virus neutralization test (sVNT) in comparison to 90% plaque reduction neutralization tests (PRNT[SUB]90[/SUB]) in human, canine, cat and hamster sera. With PRNT[SUB]90[/SUB] as reference, sVNT had sensitivity of 98.9% and specificity of 98.8% respectively. Using a panel of immune sera to other coronaviruses, we confirm the lack of cross reactivity to other coronaviruses in SARS-CoV-2 sVNT and PRNT[SUB]90[/SUB] assays, except for cross-reactivity to SARS-CoV-1 in sVNT.